Choose Broker

Step 1
Choose a broker


Please enter your User ID and Password to place trade

Share or CFD

Step 2
Select the investment product you wish to purchase

OR

Share

Purchasing shares in a company buys you part ownership of that company. You're given the right to vote on who manages the company and receive a portion of company profits through the distribution of dividends.

Example: If a share price quote is $25, then that means one share is valued at $25.

Note: Shares are also referred to as stocks, equities and securities.

CFD

Is an abbreviation for "Contract for Difference". A CFD is a 'derivative' that is derived from the underlying value of the share price. A CFD’s allow you to go long (buy the CFD) or go short (sell the CFD).

CFD's give you leverage.

Example: Buying a CFD in XYZ provides you with an opportunity to purchase the shares at a variable rates such as 10 to 1 ratio instead of the full upfront share value cost i.e. paying $1,000 instead of $10,000.

Because CFDs are traded on margin, you must maintain the minimum margin level at all times.

Note: CFD’s are not recommended for novice traders.

Order Type

Step 3
Select your type of market order


Market Order

This is a type of order that instructs to buy or sell immediately at the best price available.

Limit Order

An order placed to buy or sell a set number of shares at a specified price or better.

Stop Order

This is an order that is executable once a set price has been reached. Once the order surpasses a particular point the order becomes a market order.

Stop Limit Order

An order placed that will be executed at a specific price or better after a given stop price has been reached. Therefore it combines the feature of a stop order with those of a limit order.

Order Period

Step 4
Select the time period that you want your trade to be live/active for.


G.T.C

Stands for good till cancelled. This means once the order is placed, the order will remain in place until someone cancels the order.

Day order

An order that if not executed, will stand until the end of the trading day.

One week

An order that will stand for a full week from the time it is placed, and then be automatically cancelled at the end of this period if it has not been executed.

One month

An order that if not executed, will stand for a full month.

End of week

An order that if not executed, will stand to the end of the trading week.

End of month

An order that if not executed, will stand to the end of the trading month.

End of year

An order that if not executed, will stand to the end of the year.

Quantity

Step 5
Select the value or quantity of how many shares you want to buy

Shares
@
$

Brokerage Fee: Please select broker first to calculate brokerage*.

Nominal Value:
$71.50 AUD

Risk Management

Step 6
Select what alarms (automatic exits) you want to protect both your investments and your profits.

Take Profit
$
OR
%
Stop Loss
$
OR
%
Trailing Stop Loss
%

Take Profit

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Trailing Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Confirm

Confirm
Please confirm your order

Buy -
Order Type -
Price -
Order Period -
Brokerage 8.00 AUD
Nominal Value -
Take Profit -
Stop Loss -
Trailing Stop Loss -
Trade Date -
There was a problem with your trade ticket. Please try again.
There was a problem submitting your trade ticket. Please try again in a minute.

Order Placed Successfully


Exit Orderpad        Place another trade
Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{quote['Price Qualifier Code'] == "OPN" ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Mayne Pharma Group Limited (MYX)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

News

No News Available

{{item.Body}}



General Overview

About

Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes globally; either directly or through distribution partners and also provides contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world including:

  • Lozanoc™/Itragerm™ - super-bioavailable itraconazole used to treat fungal infections.
  • Doryx™ - delayed-release oral formulation of doxycycline used to treat acne, certain bacterial infections or as an anti-malarial.
  • Astrix™ - delayed-release low-dose aspirin used to treat cardiovascular disease.
  • Eryc™/Erymax™ - delayed-release erythromycin used in the treatment of bacterial infections.
  • Kadian™/Kapanol™ - sustained-release oral morphine used in the management of chronic pain.

A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, USA, Europe and Asia and two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

The 12,000m2 facility in Salisbury, South Australia is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods. The drug development and manufacturing operations are supported by approximately 180 staff with more than 20 formulation and analytical scientists dedicated to the development of new products. The Mayne Pharma site:

  • Is GMP compliant as certified by chief regulatory authorities (FDA, TGA and with mutual recognition from the MHRA, TPD and various Asian regulatory authorities).
  • Is licensed to handle CII/S8 compounds (controlled drug substances) and utilise chlorinated solvents and alcohols in the manufacturing process.
  • Includes an established manufacturing facility with capacity to produce 2.5 billion capsules and tablets, 100 ton of bulk product and 16 million units of liquid and cream product annually.
  • Includes extensive product development laboratory space to accommodate all analytical processes and bench scale formulation through to pilot scale manufacturing and scale-up for multiple concurrent development projects.
  • Is a centre for product development activities, from formulation and clinical trial stage, to validation and registration, to commercial scale manufacture of packaged goods ready to be dispensed.

Strategy

Mayne Pharma Group Limited strategy is to develop their business by licensing and acquiring products that they are able to market in Australia or USA and to develop partnerships for the global marketing of products developed by Mayne Pharma.

History

The history of Mayne Pharma is intricate and began with FH Faulding & Co Ltd.

From 1845 until 2001, Mayne Pharma was known as FH Faulding & Co where amongst other activities including pharmaceutical wholesaling and consumer health products, it built success around optimising the delivery of oral dosage form drugs.

In 2001, Mayne Group Ltd acquired FH Faulding & Co and then in November 2005, Mayne Group Ltd demerged the business into:

  • Mayne Pharma Limited; a global pharmaceutical company focused on research and development, manufacture, marketing and distribution of injectable and oral pharmaceuticals; and
  • Symbion Health Limited - a large Australian healthcare-focused company with leading market positions in pathology, diagnostic imaging, pharmacy and health-related consumer products.

In February 2007, Hospira Inc announced that it had completed the acquisition of Mayne Pharma Limited as it tied in with the firms skills in specialty generic injectible pharmaceuticals.

However in October 2009, the oral pharmaceutical group of Mayne Pharma Limited was purchased from Hospira by Halcygen Pharmaceuticals Ltd.

In November 2010, HalcyGen Pharmaceuticals changed its name to Mayne Pharma Group Limited, which is listed on the Australian Stock Exchange under the ASX code “MYX”.


Products

Doryx™ Capsules & Tablets

Doryx™ capsules and tablets are delayed release oral formulations of doxycycline (a tetracycline class of antibiotic), that can be used treat certain types of infections, as adjunctive treatment of severe acne and as an anti-malarial.

Doryx™ capsules and tablets contains enteric-coated pellets of doxycycline hyclate and is the only delayed release pelletised doxycycline product on the market.

Pellets are formulated to delay the release of doxycycline until the product reaches the small intestine thus reducing the potential for gastrointestinal side effects such as nausea and vomiting compared to conventional doxycycline products. Doryx™ delayed-release tablets are available in 75mg, 100mg and 150mgs.

Doryx™ delayed-release capsules are available in 50mg and 100mg. Doryx™ capsules are currently licensed and sold in Australia and Singapore. Doryx™ tablets are licensed and sold in United States. Opportunities remain for licensing in a significant number of international territories.

Mayne Pharma offers Doryx™ capsules and tablets on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Eryc™ / Erymax™ Capsules

Eryc™ capsules are a delayed release erythromycin (a macrolide antibiotic) produced by Mayne Pharma using proprietary pellet technology.

Indicated for the treatment of a wide variety of bacterial infections, Eryc™ erythromycin is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine.

Eryc™ capsules are available in two dose strengths, 250mg and 333mg.

Eryc™ erythromycin capsules are currently licensed and sold in Australia, Canada, Sweden and the United Kingdom. Opportunities remain for licensing in a significant number of international territories.

Mayne Pharma offers Eryc™ capsules on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Kapanol™ / Kadian™ Capsules

Kapanol™ and Kadian™ capsules are a sustained release oral formulation of morphine sulphate indicated for the management of moderate to severe chronic pain.

Kapanol's™ and Kadian™ drug delivery profile is achieved with Mayne Pharma’s sustained release pellet technology. This provides patients with smooth steady-state plasma levels for consistent pain relief.

Kapanol™ and Kadian™ capsules may be dosed once or twice daily to maintain therapeutic blood levels and is available in a number of flexible modes of administration (capsules, sprinkle and G-tube) and doses (10mg, 20mg, 50mg and 100mg in Australia, Canada and various other international territories).

Kadian™ capsules are currently licensed to Abbott Laboratories (as Kadian™) and Dainippon (as Kadian™) and sold in Australia, Canada and Japan and various other international territories. Further licensing opportunities remain.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Lozanoc™ / Itragerm™ Capsules

LOZANOC™ is an orally administered antifungal agent with the active ingredient itraconazole.

Itraconazole treats fungal infections by binding to fungal cytochrome P450 and disrupting the biosynthesis of ergosterol. Itraconazole consists of a 5-member triazole ring with three nitrogen atoms, which may be responsible for its broad spectrum of activity.

Developed and Manufactured in Australia

LOZANOC™ is manufactured by Mayne Pharma at their development and manufacturing facility in South Australia. Mayne Pharma is a technology-driven pharmaceutical company with a well established track record of innovation and success in developing new oral drug delivery systems.

They currently have distribution partners for LOZANOC™ in the following countries: Korea, China, Spain, Italy, Portugal and Austria. Opportunities remain for licensing in a significant number of other international territories.

SUBA™ technology brings improved bioavailability

LOZANOC™ has approximately double the bioavailability of the conventional itraconazole formulation. This greater bioavailability compared with conventional formulations is achieved using the SUBA™ manufacturing process, a proprietary technology developed by Mayne Pharma. SUBA™ technology utilises a solid dispersion of drug in a polymer matrix to improve the dissolution of poorly soluble drugs resulting in improved adsorption of these drugs in the gastrointestinal tract.

One capsule of LOZANOC™ 50mg is therapeutically equivalent to one 100mg capsule of conventional itraconazole. The recommended dose for LOZANOC™ is therefore half the recommended dose for conventional itraconazole. LOZANOC™ 50mg Capsules and conventional itraconazole 100mg capsules are not interchangeable.

this product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

LOZANOC™ and SUBA™ are trade marks of Mayne Pharma International Pty Ltd. ITRAGERM is a trade mark of ISDIN SA.

Urocarb™ Tablets

Urocarb™ Tablets contain 10 mg bethanechol chloride as the active ingredient. They are round, light pink tablets with a break-line on one side. They are supplied in bottles of 100 tablets.

Urocarb™ tablets are available via the Pharmaceutical Benefits Scheme in Australia.

The product is made in Australia and opportunities remain for licensing in a significant number of international territories.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Astrix™ Capsules & Tablets

ASTRIX™ Aspirin Capsules

Astrix™ aspirin capsules are the only enteric coated pelletised form of low-dose aspirin on the market, and are used for the same indication as Astrix™ tablets. Their enteric coat allows the release of aspirin to be delayed, until the pellets reach the small intestine, thereby reducing the risk of gastric ulceration that may be experienced with longer term use of immediate release aspirin.

Astrix™ capsules and/or tablets are currently licensed and sold in Australia, Hong Kong, Korea, Mauritius, Singapore and Sri Lanka. Opportunities remain for licensing in a significant number of international territories.

Astrix™ aspirin tablets are an immediate release low-dose form of aspirin indicated for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease.

ASTRIX™ Aspirin Tablets 112

Astrix™ tablets 112 are listed on the Pharmaceutical Benefits Scheme (PBS) in Australia and Astrix Capsules (84 pack) are available via the Repatriation Benefits Scheme (RPBS).

Your doctor will advise you whether using Astrix™ capsules or tablets as part of an overall program to manage the risk of heart attack or stroke is suitable for you. Always read the label. Use only as directed. If symptoms persist see your doctor.

Licener™ Single Treatment

Licener™ has proven its effectiveness through clinical studies on children suffering from head lice. The shampoo is soft on the skin and hair, does not sting, and does not contain chemical smelling components.

This unique treatment contains the active ingredient, Neem-extract. The natural extract ensures that the breathing apparatus of the lice are blocked, and the oxygen transportation is disrupted. The lice will suffocate within only a few minutes. The extract also completely covers the head lice eggs (nits) and the protective shell of the nits is broken down so Licener™ kills both the lice and nits in a single treatment.

Magnoplasm™

Magnoplasm™ Paste

Magnoplasm Paste has been on the Australian market for decades and is Australian made and owned. It is registered with the Therapeutic Goods Administration AUST R 29623 and sold in Australia.

It is a magnesium sulfate-glycerol paste packed into a handy to use jar of 100gms. The paste itself contains glycerol 44% w/w and magnesium sulfate dried 48% w/w.

Magnoplasm Paste exerts a powerful osmotic action on living cells. It is a useful initial treatment for boils, carbuncles and whitlows.

Directions for use: Spread (about 5mm thick) on the inflamed area needing treatment and cover with a non-adhesive dressing. Change the dressing after 12-24 hours and repeat if necessary. Magnoplasm Paste can be applied cold, straight from the jar or warmed to aid spreading.

Magnoplasm Splintex™ Gel

Magnoplasm Splintex can be used as an everyday drawing agent and is available in a convenient take anywhere pack. It is used to help draw out splinters, thorns & exudates (ooze & pus). Especially good for those hard to reach splinters under the nails and in the hands and feet.

Magnoplasm Splintex is listed as a class 1 medical device.

Available in a handy, 35g tube. Ideal for travel, first aid kits and tool boxes.

Percutane™ Pain Relief Cream & Percutane™ Sports Cream

Percutane™ Pain Relief

Percutane™ Pain Relief cream may provide rapid, long lasting relief from the pain and inflammation associated with mild arthritis, Fibromyalgia and mild Neuralgia. Relief from pain caused from the shingles rash, back, neck and shoulder pain and muscular aches and pains. Percutane™ can assist with mobility and relieve stiff joints.

Click here to learn more about Percutane™ Pain Relief Cream and view their latest TV commercial as seen on National TV.

Percutane™ Sports Cream

Percutane SportsKate HollywoodPercutane™ Sports cream designed with its sustained warming action helps prepare muscles and joints for strenuous sport or recreational activity creating the optimal physical condition to perform at your best or maintain a more active lifestyle. Percutane™ Sports cream helps revitalise tired muscles, temporarily relieve exercise induced pain and may assist in the management of sprains and muscle strains.

Ex-Hockeyroo and 2 times Commonwealth games Gold Medallist, Kate Hollywood, is one of the more recent people to discover the benefits of Percutane™.

Mayne Pharma Aspirin Tablets

Mayne Pharma low-dose Aspirin tablets are used for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease.

The 100mg product is presented in a blister pack of 112 tablets.

Mayne Pharma Aspirin is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.

Your doctor will advise you whether using this product as part of an overall program to manage the risk of heart attack or stroke is suitable for you. Always read the label. Use only as directed. If symptoms persist see your doctor.

Mayne Pharma Doxycycline Capsules

Mayne Pharma Doxycycline capsules can be used treat certain types of infections, as adjunctive treatment of severe acne and as an anti-malarial.

The 100mg product is presented in bottles of 7 and 21 capsules. The 50mg product is presented in bottles of 25 capsules.

Mayne Pharma Doxycycline is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Mayne Pharma Erythromycin Capsules

Mayne Pharma Erythromycin capsules are indicated for the treatment of a wide variety of bacterial infections.

The product comes in a 250mg dose strength and is presented in a blister pack of 25 capsules.

Mayne Pharma Erythromycin is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.


Services

Product Development

Mayne Pharma has a proven track record in the development, optimisation and scale-up of generic and branded, innovative products for over the counter and prescription purchase. In addition they also provide value added active pharmaceutical ingredients (APIs) with off-patent drugs or new chemical entities (NCEs) for local and international markets.

Mayne Pharma offers product development options in conjunction with associated services, via its product development facility which is comprised of analytical laboratories and pilot scale production facilities that allow for a continuous scale up pathway from bench scale formulation to full commercial manufacture.

All facilities have been approved by international regulatory authorities including TGA, FDA, TPD and MHRA. Furthermore Mayne Pharma meets GMP and GLP standards for clinical supplies, thus accrediting their company to fulfill your requirements to ensure your products meet international standards. Mayne Pharma has experience shipping product, including clinical trial supplies, to any location in the world.

General Services

In conjunction with full logistical, project management and technical support, Mayne Pharma offer a wide range of services that assist partners' products to reach markets fast and cost effectively.

  • Mayne Pharma are focused on providing value-added services in the areas of:
  • Oral Drug Delivery Systems
  • Liquids & Creams
  • Generic Oral product Manufacturing

Such services in these areas include:

  • Analytical Development
  • Formulation Development
  • Logistics (Distribution)
  • Manufacturing
  • Packaging Service
  • Pre-clinical and Clinical Development
  • Process Development and Scale up
  • Quality Assurance
  • Stability Services
  • Validation Services

Services for Biotechnology Companies

Mayne Pharma provides the opportunity for start-up to mature biotechnology companies to further develop their conceptual innovative ideas and turn them into a high potential reality.

Services offered to the biotechnology sector include:

  • Analytical Development
  • Formulation Development
  • Logistics (Distribution)
  • Manufacturing
  • Packaging Service
  • Pre-clinical and Clinical Development
  • Preformulation
  • Process Scale up
  • Quality Assurance
  • Stability Services
  • Validation Services

Whilst Mayne Pharma has a defined list of contract services, it should be noted that each service area is highly integrated to warrant first-class accomplishment of all designated projects.

As such, Mayne Pharma's Business Development, Intellectual Property Management, Engineering, Logistics, Clinical Development and Regulatory Affairs teams provide support services to all product developments and contract manufacturing projects.


Projects

Pellet Technology

Mayne Pharma specialises in the formulation and production of active pharmaceutical ingredients (APIs) in pellets.

They focus on all drugs in pellet form achieving a highly desired physicochemical and pharmacokinetic profile, which ensures finely controlled dosing and optimal drug efficacy. Pellets as a dose form have many advantages including maintained blood plasma levels over entire intestinal transit time and reduced gastrointestinal (GI) side effects.

The particles generated by pellet technology are generally spheroidal in shape and can have a diameter ranging from 300 to 1,700µm. The pellets are manufactured by polymer coating drug cores that can have drug loadings of up to 90%.

Pellets can be filled into hard gelatin capsules and/or sachets, or incorporated into a compressed tablet.

Mayne Pharma has developed a number of proprietary and/or patented sophisticated pellet technologies that have allowed for the formulation of pharmaceuticals with modified release profiles. Products including Eryc™ (delayed release erythromycin), Doryx™ (delayed release doxycycline) Kadian™ (extended release morphine), Astrix™ (delayed release, low dose aspirin) and pulsed release Diltiazem have established market success and generate current combined market sales in excess of US $500 million per annum.

SUBA™ Bioavailability Technology

SUBA™ technology is proprietary technology that improves the oral bioavailability of poorly soluble drugs.

The technology utilises a solid dispersion of drug in a polymer (see SUBA™ technology particle picture) to improve the absorption of drugs in the gastrointestinal tract to achieve “super bioavailability” compared to conventional formulations. This dispersion improves the dissolution of poorly soluble drugs compared to their normal crystalline form.

SUBA™ technology has been applied to improving the oral absorption of itraconazole. SUBA™ Itraconazole (improved bioavailability itraconazole capsules) has approximately double the bioavailability of the innovator formulation and can be taken without regard to meals.

Cleantaste™ Technology

Cleantaste™ is a proprietary Mayne Pharma microencapsulation technology that can;

  • Provide taste masking of unpalatable drugs
  • Improve pharmaceutical stability and/ or
  • Sustain the release of drugs.

Cleantaste™ generates microcapsules with a fine particle size (25-150µm diameter), that are small enough to be non-gritty in the mouth. This allows for a superior mouth feel compared to other microencapsulation technologies and enables incorporation into oral disintegrating, chewable and/or dispersible tablets, sachets and liquid formulations as well as hard and soft gelatine capsules.

Some 20% of the population have difficulty swallowing conventional solid oral dose forms (particularly children and the elderly). Cleantaste™ provides the opportunity to meet the needs of this market segment with formulations that are pleasant tasting and easy to swallow.


Price History

52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
Date Open High Low Close Volume

Dividend Information

Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}

Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
{{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate}} {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.DividendPayDate == '00/01/1900' ? '-' : item.DividendPayDate}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '00/01/1900' ? '-' : item.DividendReinvestmentDeadline}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

Share Statistics

  Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
  Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
{{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
Common Shareholders Shares Outstanding Shares Issued Float
{{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
Index Code Index name
{{item}} {{generalInfo.IndexMembership[item]}}
N/A N/A
Order Industry Type Code Mnemonic Reported
N/AN/AN/AN/AN/AN/A
{{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

Valuation Ratios

  P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
  Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

Financial Strength Ratios

  Current ratio Quick ratio LT debt/equity Total debt/total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
  Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
  Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

Management Effectiveness Ratios

Turnover Asset Inventory Receivables
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
Return on Average Assets EBITD Equity Investment
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
Employees Net Income Revenue
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

Growth Ratios

Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

Forecast Ratios

Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
{{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
{{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
{{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
{{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
{{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
{{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
{{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
{{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

Financial Reports

Financial Summary

Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


Accounting Notes
Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

-

- - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
Fiscal Period
Period End Date:
Period Length
Ratios Value
Analyst Footnotes

Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



Directors, Officers & Company Executives

Start Date End Date
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
{{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
No Directors, Officers & Company Executives Information Found.

Recommendation Statistics

No Recommendation Statistics

Recommendation Statistics
Recommendation Number Of Analysts
{{stats.Recommendation}} {{stats.NumberOfAnalysts}}
I/B/E/S Mean
{{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Past Broker Recommendations

No Past Recommendations

Past Broker Recommendations
  Strong Buy Buy Hold Underperform Sell Total
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

Target Price

No Target Price

Target Price
Mean {{priceTarget.Mean}}
High {{priceTarget.High}}
Low {{priceTarget.Low}}
Median {{priceTarget.Median}}
Standard Devitation {{priceTarget.StandardDeviation}}
Number Of Estimates {{priceTarget.NumberOfEstimates}}

Videos

No Videos Found

Click here to view video

{{video.summary}}




Contact Info

Mayne Pharma Group Limited

1538 Main North Road
Salisbury South, SA
Australia, 5106

Phone: +61 8 8209 2666
Fax: +61 8 8281 6998
Email: lisa.pendlebury@maynepharma.com
Website: http://www.maynepharma.com/

Click here to view the interactive map
Mayne Pharma Group Limited Google Map
Mayne Pharma Group Limited Google Map

Share Registry

Computershare Investor Services Pty Limited - Click here to view share registry profile

Phone: +61 3 9415 5000
Fax: +61 3 9473 2500
Email: investor.relations@computershare.com.au
Website: http://www.computershare.com/

452 Johnston Street
Abbotsford, VIC
AU Australia, 3067


Important Information

This profile was last edited on 10 Jun 2015.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.

Home

Search

Login

Report a bug